A 28-year-old woman from Delhi presents with a 3-year history of irregular menstrual cycles (cycles ranging from 35 to 90 days) and progressive hirsutism over the face and chest. She reports difficulty conceiving for the past 18 months despite regular unprotected intercourse. On examination, BMI is 26 kg/m², acne is present on the face, and there is moderate facial hirsutism. Pelvic ultrasound shows bilateral ovarian cysts (>10 mm) with increased stromal echogenicity. Fasting blood glucose is 98 mg/dL, and serum testosterone is 0.8 ng/mL (normal <0.7 ng/mL). LH:FSH ratio is 3.2:1. What is the most appropriate next step in the management of her infertility?

## Clinical Diagnosis and Rationale **Key Point:** This patient meets Rotterdam criteria for PCOS: irregular cycles + hyperandrogenism (hirsutism, elevated testosterone) + polycystic ovaries on ultrasound. She has anovulatory infertility and desires conception. **High-Yield:** Per current evidence-based guidelines (ESHRE/ASRM 2023, Williams Obstetrics 26e, Shaw's Textbook of Gynaecology), **Clomiphene citrate (CC)** is the **first-line pharmacological agent for ovulation induction** in women with PCOS-related anovulatory infertility, regardless of metabolic status. ## Why Clomiphene Citrate is First-Line Clomiphene citrate acts as a selective estrogen receptor modulator (SERM) at the hypothalamic level, blocking negative feedback and increasing GnRH pulsatility → ↑ FSH → follicular development and ovulation. Standard dosing: 50 mg/day for 5 days starting day 2–5 of cycle. | Feature | Clomiphene Citrate | Metformin | IVF | |---------|-------------------|-----------|-----| | **First-line for infertility in PCOS** | **Yes** | No (adjunct) | No (3rd line) | | **Ovulation rate** | 70–80% | 30–40% | N/A | | **Pregnancy rate** | 40–50% per cycle | Lower as monotherapy | 40–50% per cycle | | **Evidence base** | Strong (RCTs, guidelines) | Weaker for infertility alone | Reserved for failure | | **Cost** | Low | Low | High | **Clinical Pearl:** The landmark PPCOS II trial (Legro et al., NEJM 2007) confirmed clomiphene citrate as superior to metformin for live birth rates in PCOS infertility. Metformin may be used as an adjunct but is NOT the preferred first-line agent for ovulation induction. ## Addressing the Metabolic Argument The fasting glucose of 98 mg/dL is **within the normal range** (IFG is defined as 100–125 mg/dL per ADA criteria). BMI of 26 kg/m² is borderline overweight but does not constitute overt metabolic syndrome. While metformin has a role in PCOS management (improving insulin sensitivity, reducing androgen levels), it is **not the first-line treatment for infertility** in PCOS — clomiphene citrate holds that position per all major obstetrics and gynaecology textbooks. ## Why Not the Other Options? - **Option A (Immediate IVF):** Premature; medical ovulation induction must be attempted first. IVF is reserved for clomiphene-resistant PCOS or failed medical management. - **Option B (Spironolactone):** Addresses hirsutism only; does NOT induce ovulation. Spironolactone is also teratogenic and contraindicated when pregnancy is desired. - **Option C (Metformin first):** Metformin is an adjunct in PCOS management but is NOT the first-line agent for ovulation induction. Fasting glucose 98 mg/dL is technically normal, making the metabolic dysfunction rationale insufficient to override standard first-line therapy. **High-Yield:** Clomiphene citrate 50 mg/day × 5 days (day 2–5 of cycle) is the standard first-line ovulation induction agent in PCOS-related anovulatory infertility [Williams Obstetrics 26e, Ch 32; ESHRE PCOS Guidelines 2023].